I have always used Humalog (Lispro) in pumping and haven't tried Apidra. I'm going to see if I can get a few vials to check out also.
The clinical trial which resulted in the FDA approval of Apidra was actually a comparison between the newer insulin (Apidra) and the older one (Lispro). This is a desription of the results from this trial which I picked off an internet site. It reports that any differences are insignificant:
The approval of Apidra(R) for pediatric use is based upon a 26-week,
phase III, open-label, active control study of Apidra(R) in comparison with
insulin lispro in 572 children and adolescents (4 - 17 years of age) with
type 1 diabetes. Study patients received insulin glulisine or lispro 0-15
minutes premeal. These patients received concomitant treatment with insulin
glargine once daily or NPH twice daily as basal insulin. The majority of
the patients received insulin glargine as part of their basal-prandial
regimen (69.7% and 72% in the Apidra(R) and insulin lispro treated groups,
The study compared the efficacy of Apidra® to insulin lispro in terms
of change in glycohemoglobin (HBA1c), which is the amount of sugar bound to
hemoglobin in the blood. The change in HBA1c from baseline to endpoint for
Apidra® and insulin lispro were similar. The mean HBA1c change in the
Apidra® population was +0.10% (+ or - 0.08) and +0.16% (+ or - 0.07) in
the lispro group. The difference between the two treatments for this
measure was -0.06%, or almost zero, with a 95% confidence interval of
(-0.24; 0.12). HbA1c at baseline was 8.20% (+ or - 1.05) in the glulisine
group and 8.17% (+ or - 1.02) in the lispro group, HbA1c at endpoint was
8.31% (+ or - 1.37) in the glulisine group and 8.37% (+ or - 1.32) in the
lispro group. Postprandial glycemic control, as assessed by the
self-monitored blood glucose values and blood glucose excursions, was
similar in both treatment groups at endpoint.
No noteworthy differences existed between treatment groups in the
number of study patients reporting hypoglycemia, which is the most common
adverse reaction of insulin therapy. This included hypoglycemia reported as
a serious adverse reaction, which occurred in 7.2 percent of study patients
in the glulisine group and 8.1 percent of those in the lispro group.
I think that the lower incidence of hypoglycemia with the Apidra is interesting and could be significant. What you were told about its ability to withstand higher ambient temperatures without losing potency is most definitely a plus, especially in pump use where it could be exposed to warmth all day long.